Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-46444
Titel: Polyclonal antibodies towards abrin and ricin-design and potential application for mass spectrometry-based analysis of human biosamples
VerfasserIn: Vollmer, Aline C.
Fecher-Trost, Claudia
Jung, Martin
Cole, Marnie
Arnst, Tilman F.
Flockerzi, Veit
Wagmann, Lea
Meyer, Markus R.
Sprache: Englisch
Titel: Archives of Toxicology
Bandnummer: 99
Heft: 11
Seiten: 4399-4410
Verlag/Plattform: Springer Nature
Erscheinungsjahr: 2025
Freie Schlagwörter: Abrin
Ricin
Polyclonal antibodies
Magnetic beads
Affinity column chromatography
Liquid chromatography-mass spectrometry
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: The analysis of highly toxic proteins such as abrin and ricin is challenging but comprehensive analytical methods are essential for their unambiguous identification after ingestion. This study pursued three primary aims at detecting abrin and ricin in human biosamples while ensuring that laboratory staff remain protected from direct exposure to these toxic pro teins. First, two polyclonal antibodies (pAB) against specific peptides of abrin-A and ricin should be produced. Thereby, antibody epitope mapping was performed, which proved that both pAB recognize specifically their target peptide. Second, an affinity column chromatography-based assay was developed, and finally, the generated pAB should be tested using two different approaches (A and B) for their application in mass spectrometry (MS)-based bioanalytical workflows. Approach A used blood and urine samples submitted to the author’s laboratory after suspected ricin intake. Samples were prepared for nanoLC-MS analysis using affinity column chromatography, gel electrophoresis, and overnight trypsin digestion. Analysis resulted in the confirmation of ricin presence in both plasma and urine. Approach B included the enrichment of an abrin-A peptide and ricin-peptide using affinity column chromatography directly followed by LC-Orbitrap MS with a detection limit of at least 5 ng/mL in plasma and validation according to international recommendations. Since approach B is much more time-efficient and can be applied throughout laboratories due to the less equipment required, this strategy deserves further focus, especially in a clinical setting.
DOI der Erstveröffentlichung: 10.1007/s00204-025-04132-x
URL der Erstveröffentlichung: https://link.springer.com/article/10.1007/s00204-025-04132-x
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-464446
hdl:20.500.11880/40724
http://dx.doi.org/10.22028/D291-46444
ISSN: 1432-0738
0340-5761
Datum des Eintrags: 23-Okt-2025
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Information
In Beziehung stehendes Objekt: https://static-content.springer.com/esm/art%3A10.1007%2Fs00204-025-04132-x/MediaObjects/204_2025_4132_MOESM1_ESM.pdf
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Experimentelle und Klinische Pharmakologie und Toxikologie
M - Medizinische Biochemie und Molekularbiologie
Professur: M - Prof. Dr. Veit Flockerzi
M - Prof. Dr. Markus Meyer
M - Keiner Professur zugeordnet
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
s00204-025-04132-x.pdf1,33 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons